在潜在可切除的肺状细胞癌中,在新辅助化学免疫治疗后的临床因素和主要病理反应
Ye Wang1,2, Yingqiu Song1, Runze Wang1
1Department of Radiotherapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning, China.
Frontiers in oncology
|April 29, 2024
概括
在接受新辅助化疗免疫疗法 (NCIO) 的肺平细胞癌 (LUSC) 患者中,主要病理反应 (MPR) 由治疗前的淋巴细胞水平,瘤负担,N分类,放射性反应,肺 atelectasis 和 PD-L1 表达预测. 一个名图模型准确地预测了MPR,改善了LUSC的个性化治疗.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 医学瘤学 医学瘤学
背景情况:
- 主要病理反应 (MPR) 是肺状细胞癌 (LUSC) 患者的关键预后指标.
- 在LUSC中新辅助化学免疫治疗 (NCIO) 后的MPR预测因素仍然不完全理解.
- 识别这些预测因素对于优化治疗策略至关重要.
研究的目的:
- 调查影响潜在可切除LUSC患者进行NCIO的MPR实现的临床因素.
- 开发MPR的预测模型,以指导个性化治疗.
主要方法:
- 对91名接受NCIO和手术切除的LUSC患者 (IIB-IIIC阶段) 的回顾性分析.
- 评估NCIO前的临床,血液学,成像学和PD-L1表达数据.
- 基于MPR的独立预测因子开发了一个名ogram.
主要成果:
- 病理性完全缓解率为65%,其中43例病理性完全缓解 (pCR).
- 独立预测MPR的预测因素包括治疗前的淋巴细胞水平,瘤负担,N分类,放射反应,肺透症和PD-L1表达.
- 开发的诺米图实现了0.914的AUCMPR预测.
- MPR与明显改善的无疾病生存率 (DFS) 有关.
结论:
- 治疗前的因素,如淋巴细胞水平,瘤负担,N分类,放射性反应,肺透症和PD-L1表达是治疗NCIO的LUSC患者中MPR的显著预测因素.
- 经过验证的名图表作为一个有价值的工具来预测MPR和个性化治疗潜在的切除LUSC.
- 实现MPR与更好的长期结果相关,强调其在LUSC管理中的重要性.
更多相关视频
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.8K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
